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Latar belakang: Meningioma merupakan ketumbuhan otak yang biasa berlaku 
dikalangan orang dewasa iaitu sebanyak 20% daripada keseluruhan jenis ketumbuhan 
otak. Selain daripada kadar tisu ketumbuhan yang dibuang dan gred WHO, pembetukan 
salur darah juga merupakan antara faktor prognostik yang dipengaruhi oleh MMP-2. 
Kajian ini bertujuan untuk melihat kaitan antara gred dan kadar pembetukan salur darah 
dalam meningioma dengan ekpresi MMP-2. 
 
Kaedah: Ini adalah satu kajian rentas yang dijalankan ke atas 99 kes meningioma yang 
berbeza gred dalam tempoh Januari 2008 hingga Disember 2017. Semua kes telah dilihat 
semula dan ujian antibody Ki67, MMP-2 dan CD34 telah dijalankan. Ujian ‘Pearson chi 
square’ dan ‘Fischer exact’ digunakan untuk melihat kaitan antara ekpressi MMP-2 
dengan gred meningioma dan kuantiti pembetukan salur darah. 
 
Keputusan: Sejumlah 99 kes meningioma terdiri daripada pesakit yang berumur 23 
hingga 75 tahun. Kebanyakannya adalah daripada golongan wanita (74%). Kajian ini 
mempunyai sebanyak 85 kes gred rendah (Gred I) dan 14 kes gred tinggi (11 = Gred II, 
3 = Gred III). ‘Meningothelial’, ‘Transitional’ dan ‘Fibroblastic’ adalah jenis 
meningioma yang paling kerap berlaku. Enam puluh dua daripada 85 gred rendah dan 10 
daripada 14 kes gred tinggi mempunyai ekspresi MMP-2 yang tinggi, tetapi ia tidak 
signifikan, p > 0.950. Kebanyakan kes meningioma mempamerkan kuantiti pembetukan 
salur darah yang rendah iaitu skor 1+ (54/99) dan 2+ (33/99). Empat puluh dua daripada 




Kesimpulan: Semua kes meningioma menunjukkan ekpresi MMP-2. Kebanyakan kes 
juga menunjukkan quantiti pembetukan salur darah yang rendah dan antara kes-kes ini, 
ada yang menunjukkan ekpresi MMP-2 yang tinggi. Tetapi semua ini tidak signifikan. 
Untuk kajian di masa hadapan, lebih banyak kes gred tinggi diperlukan dan jenis antibodi 












































Background: Meningioma is the most common intracranial tumour in adults which is 
20% of all primary intracranial tumours. Besides extent of tumour surgical resection and 
WHO grading, angiogenesis is also one of the prognostic factors, which is influenced by 
MMP-2. Our study aimed to determine the association of these prognostic factors with 
expression of MMP-2 in meningioma. 
 
Methodology: A cross sectional study was conducted on 99 samples of meningioma of 
different grades diagnosed from January 2008 until December 2017. All samples were 
re-reviewed and stained with Ki67, MMP-2 and CD34 immunohistochemistry markers. 
Pearson chi square and Fischer’s exact test were used to examine the association between 
MMP-2 expression with WHO grades and Microvascular Density (MVD). 
 
Results: A total of 99 cases consists of patients aged between 23 to 75 years old. Majority 
of patients were female (73.7%). This study consists of 85 cases of low-grade 
meningioma (Grade I) and 14 cases of high-grade meningioma (11 = Grade II, 3 = Grade 
III). The most common subtypes are meningothelial, transitional and fibroblastic. Sixty 
two out of 85 cases of low-grade and 10 out of 14 cases of high-grade shows high MMP-
2 expression, however they were not significant, p >0.950. Most of the cases in this study 
exhibits low level of angiogenesis with MVD score of 1+ (54/99) and 2+ (33/99). Out of 
the 54 cases that scored 1+, 42 expressed high MMP-2. However, this is not significant.  
 
Conclusion: MMP-2 were expressed in all low- and high-grade meningiomas with 
varying intensity. Majority of cases exhibit low quantity of angiogenesis and among these 
cases, mostly expressed high MMP-2. However, these findings were not significant. In 
 x 
future study, more higher grade meningioma is required to prevent bias in analyzing data. 
A more specific immunohistochemical marker should be used to evaluate angiogenesis 
to achieve accurate scoring. 
 




































1.1 Overview of Meningioma 
 
Meningioma is a benign, slow-growing tumour that occurs in adult and it is one 
of the most common tumour of the central nervous system (CNS). In the USA, it accounts 
for 36% of all brain tumours overall (1). In other parts of the world such as France, Italy, 
Australia and Japan, report showed an increased trend of primary brain tumours and in 
particular, meningioma, over the past decades (2). However, this increment is thought not 
to reflect the actual incidence due to several factors: 1) aging of the population 2) 
improvement of the health care facilities and 3) higher rate of histological conformation 
(2). The Global Cancer Statistic 2018 (3) revealed that brain and nervous system tumour 
contribute 1.6% of new cases from all cancer and 2.5% of death. However, the incidence 
according to specific brain tumour types are not available in this report.  
In Malaysia, brain tumour is considered uncommon as compared to other tumours. 
The Malaysian National Cancer Registry Report for 2007 – 2011 (4) reported that the 
brain and nervous system tumour were ranked as 11th most common in males and 13th in 
females. The Chinese have the highest incidence rate and followed by Malay and Indian. 
Incidence according to different tumour subtypes were also not included in this report. 
There should be a proper data collection on the specific types of brain tumour in Malaysia 
which could accurately reflects the tumour burden. This can guide future research towards 
advancement in treatment and healthcare plan in Malaysia. This also should apply to other 
tumour besides brain tumour. 
Yusof et al. (5) reported that the incidence of brain tumour in North East Malaysia 
is low (0.4 per 100,000 population) in 1996 and meningioma was the second most 
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common brain tumour after neuroglial tumour. One study conducted from 2011 to 2014 
to determine the distribution pattern of brain tumour in Hospital Universiti Sains 
Malaysia (HUSM), Kelantan and revealed that meningioma is the most frequent tumour, 
which accounts about 36.4% from all types of brain tumour (6). The higher incidence of 
meningioma in Kelantan, particularly in USM is because it is the referral center for brain 
tumor for east coast region and thus, this study provides the descriptive distribution for 
Kelantan and Terengganu. The incidence of brain tumour in Sarawak is 4.6 per 
100,000/year. Sarawak General Hospital reported about 35% of operated cases between 
2000-2001 were meningioma and 32.3% between 2009-2012 (7). 
There are several risk factors that contribute to development of meningioma. 
Ionizing radiation is one of the established environmental risk factors, with higher risk 
among people who were exposed in childhood than as adults (1). There is also higher 
incidence in female compare to male patient which suggest that female hormone could 
play a role via estrogen and progesterone receptor (8). Several studies reported a possible 
association between meningioma and breast cancer (9) (10). Both share the same common 
risk factors such as endogenous and exogenous hormones as well as shared genetic 
predisposition (11). Michaud et al. (12), found a positive association between risk of 
meningioma and body fatness which measures BMI, waist circumference and weight. 
The exact mechanism of this is unclear, but possible mediators could be involved which 
include hormonal factors, immunologic response and levels of insulin or insulin-like 
growth factors.  
According to the WHO Classification of Tumours of the Central Nervous System 
Revised 4th edition 2016 (1), meningioma is divided into three grades, namely Grade I, 
Grade II and Grade III. Approximately 90% of meningiomas are benign (Grade I) and 
have slow growth, with incidence increasing with age (11). It is associated with relative 
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good outcome (13), however, a significant number of cases relapses occur among benign 
meningiomas (14). The remaining percentage of meningioma are atypical (Grade II) and 
anaplastic (Grade III), which represent a major challenge to neurosurgeons (15). Atypical 
(Grade II) meningiomas occupy an intermediate risk group between benign (Grade I) and 
anaplastic (Grade III) meningiomas. They carry a several-fold increased risk of 
recurrence, as well as an increased rate of mortality (16). As for meningioma Grade III, 
the prognosis is poor and complete or subtotal resection may prolong the patients’ 
survival (17). 
Each grade can be further divided into several subtypes (Table 1). The most common 
subtypes are meningothelial, fibrous and transitional meningioma (Grade 1) (1).  
 
Table 1.1: 2016 WHO classification for meningioma. 
























The grading system is mainly based on histomorphology criteria and number of mitosis 
(1) (Table 1.2). 
Table 1.2: Histomorphology criteria for grading of meningioma. 
Grade I Grade II Grade III 
i) less than 4 
mitotic figures 
i) 4 - 19 mitotic figures/10 HPF 
OR 
ii) Brain invasion OR 
iii) Three of these histologic 
features: 
a. Increased cellularity 
b. Small cells with high N/C 
ratio 
c. Large and prominent 
nucleoli 
d. Patternless or sheet-like 
growth 
e. Foci of "spontaneous" or 
geographic necrosis 

















In addition to histological grade, the other most powerful histological 
prognosticator for the outcome of meningioma is proliferation index (18). Many previous 
studies that have been carried out measuring Ki67 proliferation index in predicting 
behaviour of meningioma. Ki67 is one of the various immunohistochemical marker that 
is widely used to measure cell proliferation. Ki-67 antigen is a protein expressed only in 
proliferative phase of cell cycle, and can be detected on formalin fixed paraffin embedded 
tissue sections (19).  
A literature review done by Abry et al. (20) showed positive correlations between 
Ki67/MIB-1 and tumor grade in human meningiomas in all 53 articles. However, the 
Ki67 labelling index varied considerably from one articles to another. This highlight 
several factors that contribute to these variations which includes block selection with 
representative tumor tissue for calculation, interobserver variability and non-
standardization of Ki67 immunostaining procedure between laboratories. 
There were conflicting reports in the literature about different histological subtype 
on Ki67 proliferation index. Some studies showed that there is positive correlation (19) 
(21) and others showed no correlation between subtypes of meningioma (20) (22). Other 
studies also had been done evaluating the correlation between Ki67 with brain invasion, 
recurrence, location of the tumor and other clinicoparameters (age, gender, progesterone 
receptor) (22) (23) (24) (25). Variable results were obtained from these studies. However, 
most studies agreed that Ki67 represent as a prognostic marker in human meningioma in 
term of histological grade and recurrence. 
The most common chromosomal change is Monosomy 22 which is seen in 40-
70% of all grades of meningioma (26).  Other cytogenetic changes includes deletion of 
chromosome 1p in atypical meningioma that correlates with shorter progression-free 
survival (27), losses of chromosomes 6q, 9p, 10, 14q, and 18q (26) and gains of 
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chromosomes 1q, 9q, 12q, 15q, 17q, and 20q (1). Meningioma are also found to be closely 
related to tumor suppressor syndrome NF2 and 50–75% of patient with NF2 have risk to 
develop one or more meningioma in their lifetime (28). Currently, studies have identified 
several new recurrent mutations through next-generation sequencing approaches and is 
present in 40% of sporadic meningioma. These genes are pro-apoptotic E3 ubiquitin 
ligase TNF receptor-associated factor 7 (TRAF7), the pluripotency transcription factor 
Kruppel-like factor 4 (KLF4), the proto-oncogene v-Akt murine thymoma viral oncogene 
homolog 1 (AKT1), the Hedgehog pathway signaling member smoothened (SMO), and 
the oncogene PIK3CA (29) (30) (31). However, there are still around 20% of meningioma 
that have no identifiable oncogenic driver mutation (32). In future, these molecular 
advances will influence the classification and prognosis of meningioma, like in other 
Central Nervous Tumour such as medulloblastoma and glioblastoma. The management 
will also be changed due to the discovery of new therapeutic agents. 
 
1.2 Matrix Metalloproteinase-2 (MMP-2) 
 
Matrix metalloproteinases (MMPs) belong to a super family of endopeptidases 
which consists of over 20 enzymes. These enzymes are produced by various cells, 
including epithelial cells, fibroblasts, and inflammatory cells (33). MMPs are subdivided 
into 5 groups based on their structure and/or substrate specificities; matrilysins, 
collagenases, stromelysins, gelatinases and membrane-type MMPs (34). They are 
expressed only when needed for tissue remodelling. However, increased expression has 
been associated with many pathological conditions, such as rheumatoid arthritis and 
periodontitis (35). Many studies have been done on MMPs and the more recent advanced 
in technological development allows more understanding of the role of MMPs especially 
in the regulation of the tumor microenviroment (36).   
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MMPs contribute to the carcinogenesis at multiple stages; remodelling of extracellular 
matrix during early steps, followed by induction of angiogenic switch, further up-
regulation of MMPs leads to degradation of the basement membrane and allows the 
tumour cells to invade into surrounding stroma and lymphovascular channels, and 
providing a favourable microenvironment at distant sites of metastasis (37). Clinical 
study from Jäälinojä et al. (38) suggest that MMP-2 is associated with histological 
malignancy such as anaplastic astrocytoma, glioblastoma and metastatic brain tumour 
and poor survival in brain tumour. 
The two most widely studied MMPs are MMP-2 and MMP-9 (39). There are 
conflicting data between studies regarding the role of MMPs in the recurrence and 
invasiveness of meningioma, as well as the degree of expression in different grades and 
subtypes. Some studies showed evidence of high expression of both MMP-2 with 
recurrence and invasiveness (40), some studies only demonstrated only MMP-9 
involvement, and not MMP-2 (41) (42). There is a conflicting findings with respect to 
this MMP-2 and MMP-9 and expressions of histological subtypes: positive correlation 
(43) and negative correlation (44), thus routine screening with these markers will not 
reveal any new diagnostically or prognostically relevant information. 
 
1.3 Role of MMP-2 in angiogenesis  
 
Angiogenesis is the process by which tumors induce the blood supply crucial for 
growth and progression. It is a complex process which involves multiple steps and is 
initiated by the release of proangiogenic factors (eg. VEGF, TNF-𝛼) from inflammatory 
cells, mast cells, macrophages or tumour cells (45). High quantity of neoangiogenesis 
appears to be significantly associated with a higher proliferation index of meningiomas, 
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and it seems to represent a negative prognostic marker associated with shorter overall 
survival and higher recurrence risk in completely resected tumors (19). 
MMPs are clearly implicated in angiogenesis especially MMP-9, which is one of the 
angiogenesis regulator in meningioma (19). The role of MMPs in angiogenesis is to 
degrade the basement membrane and other ECM components, allowing endothelial cells 
to detach and migrate into new tissue and releasing ECM-bound proangiogenic factors 
(eg vascular endothelial growth factor, VEGF; bFGF, basic fibroblast growth factor; 
TGF𝛽, transforming growth factor-𝛽) (37). The role of MMP-2 in stimulation of 
angiogenesis has been in proven in several studies. For example; tumors expressing 
MMP-2 have more proliferating vasculature at the tumour-brain interface than MMP-2 
negative tumours (46) and implantation of tumour cells into either MMP-2 or MMP-9 
knockout mice shown to have reduced tumour-induced angiogenesis compared to 
implantation into wild type mice (34). 
Current treatment for meningiomas involve surgery, radiation therapy, and 
stereotactic radiosurgery. However, with the new understanding of angiogenesis in 
meningioma, patients are amendable to antiangiogenic therapy, particularly in patients 
with high grade or recurrence after surgery. Many antiangiogenic drugs are currently 
being used in clinical trials, i.e, becacizumab, sunitinib, and vatalinib, and have shown 
potential efficacy in uncontrolled studies and should be investigated further (47). Studies 
are now directed towards identifying specific MMPs that mediate the angiogenic response 
for the purpose of targeted treatment, thus being able to disrupt tumour neovascularization 







1.4 Objective  
 
• General objective 
To determine the expression of MMP-2 in meningioma in relation to its 
prognostic factors.  
• Specific objectives 
- To determine the expression of MMP-2 in different grades of meningioma. 
- To determine the expression of MMP-2 with angiogenesis in meningioma. 
- To determine the association between expression of MMP-2 with tumour grades 
and angiogenesis in meningioma. 
- To determine the association between angiogenesis and different grades of 
meningioma. 
 
1.5 Research hypothesis 
 
• There is positive association between expression of MMP-2 with tumour grades 

























2.1 Study protocol 
 
Title: Expression of matrix metalloproteinases (MMP-2) in prognostication of 
meningioma 
Investigator: Dr Maryam Binti Ahmad Sharifuddin (MPATH (Histopathology) student 
from HUSM) 
Supervisor: Professor Dr Hasnan Jaafar (Pathology department of HUSM) 
Co-supervisor: Dr Sharifah Emilia Tuan Sharif (Pathology department of HUSM) 
 
Introduction 
Meningioma is the most common primary intracranial tumour (1) and the reported 
incidence is about 36% in the USA (2). In Malaysia, there is no specific data regarding 
meningioma reported in the Malaysian National Cancer Registry Report 2007-2011. 
However, there are studies that provide the descriptive data of brain tumour in Sarawak 
(2009-2012) and East Coast, Malaysia (2011-2014). Both regions reported meningioma 
being the most common brain tumour accounting for 32.3% and 36.4%, respectively (3) 
(4). Meningioma usually occurs in adults in 6th decades of life and the risk increases with 
age (5).  It is uncommon in children with incidence rate of only 2.8% of all pediatric 
primary brain tumour (5).  
Meningioma is diagnosed base on characteristic radiological features and 
histopathologic examination. The WHO Tumour Classification of the CNS (2) divided 
meningioma into 3 grades and 15 subtypes. The grading is based mainly on mitotic count 
and certain histological features. It has important implication on the patient management 
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and prognosis. Ninety percent of meningioma are benign and 10% are atypical (5-7%) 
and anaplastic (1-3%) meningiomas (6).  
 
Literature review 
The Matrix Metalloproteinases (MMPs) are a family of zinc-containing 
endopeptidases which consists of 20 members. They are divided into six groups based on 
several distinct domains; collagenases, gelatinases, stromelysins, matrilysins, membrane-
type MMPs, and other non-classified MMPs (7). MMP-2, also known as Gelatinases A, 
belongs to the gelatinases group, together with MMP-9. 
MMPs are not only involved in tissue remodeling, development and wound 
healing, but also contribute to tumorigenesis and progression of various tumour (8). They 
regulate the growth of tumour cells, which eventually leads to invasion and metastasis. 
High levels of certain MMPs are shown to have poorer prognosis (9), for example, MMP-
2 overexpression in ovarian epithelial carcinoma (10), laryngeal cancer (11), gastric 
cancer (12), primary melanoma (13) and prostate cancer (14). 
MMPs are also involved in angiogenesis. Angiogenesis is a complex process 
which is an important component in tumor development. It is regulated by many pro-
angiogenic growth that is secreted by tumour cells. Many studies have proven that higher 
quantity of angiogenesis is related to higher tumour grade and poorer prognosis (15) (16) 
(17). Brain tumour are highly vascularized tumour, thus many anti-angiogenic treatments 
such as Neovastat and Suramin, were developed to target this process (18). Certain drugs 
such as VEGF inhibitor can serve as a possible safe treatment option (19), while others 
are still under clinical trials.  
MMP-2 is the most studied for their role in angiogenesis. MMP-2 together with 
integrin 𝛼v𝛽3 on the surface of vessels undergoes active remodelling in response to 
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angiogenic stimulus (18) (20). Previous studies have focused on establishing the role of 
MMP-2 in meningioma, in particular as it relates to histological grades, tumor recurrence, 
brain invasion, and peritumoral edema (1) (21) (22) (23). However, no study have been 
done specifically to evaluate the role of MMP-2 in relation to angiogenesis in 
meningioma.  
 
Rationale of study 
 
• Previous studies have focused on establishing the role of MMP-2 in meningioma, 
in particular as it relates to histological grades, tumour recurrence, brain invasion, 
and peritumoral oedema, however the data is conflicting. 
• The relationship between MMP-2 expression and angiogenesis has been 
previously reported. However, no study has been done specifically to evaluate the 
role of MMP-2 in angiogenesis in meningioma. 
• We hope this study can provide the evidence of positive correlation between 
MMP-2 and the prognostic factors of meningioma. Therefore, in future MMP-2 
can be a useful and practical assessment tool for the pathologist and surgeon as it 
provides information on the prognostication and can predicts the outcome of 
treatment or recurrence in patient. 
• As for the patient, MMP-2 also can be a potential therapeutic target and the use 
of their inhibitors may significantly improve the outcome after operation 







There is positive association between MMP-2 with tumour grades and angiogenesis.  
 
Objective of the study 
General objective 
• To determine the expression of MMP-2 in meningioma in relation to its 
prognostic factors.  
 
Specific objective 
• To determine the expression of MMP-2 in different grades of meningioma. 
• To determine the expression of MMP-2 with angiogenesis in meningioma. 
• To determine the association between expression of MMP-2 with tumour grades 
and angiogenesis of meningioma. 













Material and methodology 
Study Design 
This is a cross sectional (retrospective study). 
 
Target population 
All patient diagnosed with meningioma in Hospital Universiti Sains Malaysia from 
January 2008 until December 2017. 
 
Sample size determination 
Sample size is calculated based on Two proportion formula, using Sample Size Calculator 
version 3.1.2. 
 
To associate the expression of MMP-2 with tumour grades. 
P0 = Proportion of high MMP-2 in patient with low   
tumour grades   
= 0.16* 
 




 = Significance level                                                                          = 0.05 
Power                                                                                                   = 0.8  
 
Sample size calculated                                  = 62 
 
*[Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S. Matrix 
metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the 
recurrence of intracranial meningiomas. J Neurooncol 2004;66:29-37.](24) 
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To associate the expression of MMP-2 with angiogenesis in meningioma. 
P0 = Proportion of high MMP-2 in patient with low 
angiogenesis in meningioma   
= 0.19* 
 
P1 = Proportion of high MMP-2 in patient with high 
angiogenesis in meningioma 
= 0.4 
 
 = Significance level                                                                                                 = 0.05 
 
Power  = 0.8                                                                                                                     
Sample size calculated  = 82 
 
*[ Zhai L.L, Wu Y, Huang D.W, Tang Z.G. Increased matrix metalloproteinase-2 
expression and reduced tissue factor pathway inhibitor-2 expression correlate with 
angiogenesis and early postoperative recurrence of pancreatic carcinoma. Am J Transl 
Res 2015;7(11):2412-2422.](25) 
 
Based on the calculation, it is decided that we are going to use n = 82 samples for the 











Convenient sampling method will be used. Cases will be retrieved from the computerized 
registry data (LIS and PATHOS system) of the Department of Pathology, Hospital 
Universiti Sains Malaysia, Kubang Kerian, Kelantan. All cases of meningioma diagnosed 
between January 2016 – December 2017 that fulfill the inclusion criteria will be included 
in the sampling. Paraffin tissue blocks for all cases and its respective Hematoxylin and 
Eosin (H&E) stained slides will be retrieve from the tissue archive. Based on the H&E 
slides, the slide with the most tumor tissue will determine the choice of tissue block for 
immunohistochemistry study. Only one representative tissue block from each case will 
be chosen for each case. 
The inclusion and exclusion criteria are as follows: 
• Inclusion criteria 
All cases diagnosed histologically as meningioma of various grades. 
• Exclusion criteria 
Case excluded from this study were those with unavailable or missing paraffinized 
tissue blocks and paraffinized tissue block that are inadequate tissue or unsatisfactory 
for immunohistochemical study. 
 
Research tools 
• Paraffin blocks of patient will be used for sectioning and immunohistochemistry. 
• Immunohistochemistry stains (monoclonal mouse anti-human CD34 Class III, 
rabbit monoclonal anti-Ki67 antibody and rabbit polyclonal anti-MMP2 
antibody). 
• Secondary antibody (labelled polymer-HRP, Dako EnvisionTM + Dual Link 
System-HRP, DAB+) 
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Immunohistochemistry (IHC) staining procedure 
Tissue sections of 3-4µm thickness will be cut and transferred to poly-L-lysine precoated 
slides. The slides will undergo deparaffinization and rehydration process with xylene and 
four different alcohol solutions of descending concentration. This is followed by antigen 
retrieval process using heat-induced epitope retrieval method via pressure cooker 
(pressure cooker WMF Perfect) for 3 minutes. Antigen retrieval buffer (10mmol/L Tris 
buffer, 1mmol/L EDTA, pH 9.0) is used. Subsequently, peroxidase blocking is applied 
for 5 minutes. For MMP2 IHC test, the peroxidase blocking step was carried out after 
overnight incubation of the primary antibody. The slides will be incubated with the 
primary antibody (anti-Ki67; 1:200, anti-CD34; 1:100 and anti-MMP2 antibody; 1:500) 
for overnight at 4°C using Squenza Immunostainer (Shandon Sequenza). Then secondary 
antibody (labelled polymer-HRP, Dako EnvisionTM + Dual Link System-HRP, DAB+) 
will be applied and incubated for 30 minutes at room temperature, followed by incubation 
with 3,3’-diaminobenzidine (DAB) solution for 5 minutes. Finally, it is counterstained 
with Harris Hematoxylin for 5 seconds, followed by dehydration process. For the control 
tissue, neurofibroma will be used for anti-MMP2 whereas tonsil tissue will be used for 










Immunohistochemistry (IHC) scoring 
The slides will be examined under light microscope. For Ki67 scoring, it is recorded as 
percentage of positively stained tumor nuclei (brown satining) per 1000 tumor cells. The 
cell counts are performed in regions of maximum immunoreactivity (hot spot) under high 
power objective (x400). According to Perry et al. (26), Ki67 value is categorized into 
three grades;  
• < 4%  = WHO Grade I 
• >4%   = WHO Grade II 
• >20% = WHO Grade III 
The expression of MMP-2 will be evaluated by IHC scoring as the sum of the frequency 
and the intensity according to scale used by Strojnik et al. (27). Twenty representative 
fields were counted, and the IHC scores were determined. The total score includes the 
sum of the frequency of tumour cells that are stained and intensity of the cytoplasmic 
staining.  
Frequency: 
• Score 0 indicates no staining of tumour cells 
• Score 1 for 0-29% positive tumour cells 
• Score 2 for 30-60% 
• Score 3 for 61-100%   
Intensity 
• Score 0 indicates no staining of tumour cells 
• Score 1 for weak staining of tumour cells 
• Score 2 for moderate staining of tumour cells  
• Score 3 for strong staining of tumour cells   
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Total score of 4 and higher is considered ‘high expression’, whereas score of 3 or less is 
considered ‘low expression’. 
Assessment for angiogenesis will be using CD34 immunohistochemistry stain. A brown 
staining of a single endothelial cells or clusters of endothelial cells, with or without a 
lumen is considered as an individual vessel. According to Weidner et al. (28), the total 
number of microvessels count in three fields (400x), will be calculated as mean value and 
recorded as the microvessels density (MVD). The MVD will be given a score as follows:  
• Score 1+ for MVD value between 0 - 33  
• Score 2+ for MVD value between 34 - 67 
• Score 3+ for MVD value between 68-100 
• Score 4+ for MVD value more than 100  
 
Statistical analysis 
All data will be entered and coded in SPSS version 26.  
Descriptive data: 
• Frequency and percentage will be presented for categorical data. 
• Mean and standard deviation will be presented for numerical data. 
Univariable: 
• Pearson chi square test will be use to determine the association between MMP-2 
expression with different grades of meningioma and also to determine the 
association between angiogenesis and tumour grades. 
• Fisher’s exact test will be use to determine the association between MMP-2 





Ethical approval will be obtained from Human Research Ethics Committee of Universiti 
Sains Malaysia. Approval will be obtained from Director of Hospital Universiti Sains 
Malaysia to access patient’s folder and also from Head of Department Pathology to use 























Table 2.1. Clinicopathological characteristic. 





  Female 






  Malay 
  Chinese 







Histological subtypes   
WHO Grade 
  Grade I 
  Grade II 





  Yes  








Table 2.2. Association between MMP-2 expression and grade. 






  Low  
  High 
   
 
 
Table 2.3. Association between MMP-2 expression and Microvascular density (MVD). 










  Low 













Table 2.4. Association between grade and Microvascular density (MVD). 










  Low  
  High  











Meningioma Ca$eS diagnosed from January 2008 - December 2017 
SAMPLING FRAME 
Histopathological examination reports and clinical data will be obtained from 
the database of 'Pathos' and 'LIS' in the Department of Pathology,~ 
Random sampling will be carried out to meet the sample size requirement . 
The sampling will be referring to the inclusion and exclusion criteria. 
STUDY SUBJECT 
Retrieve blocks (paraffin embedded tissues and !f~ slides) 
'-------
3 s.ections at 4!-tm thickness of 
representative tissue block 
lmmunohistcchemistty stains 
Exclude fTom study 
CDl4 I 
Determine the WHO grading of 
meningioma based on morphology 






OAT A COllECTION & ANALYSIS 
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